Showing 921-930 of 951 results for "".
- Rare Genetic Mutations Linked to Parkinson Disease Identified in Pilot Studyhttps://practicalneurology.com/news/rare-genetic-mutations-linked-to-parkinson-disease-identified-in-pilot-study/2469313/In the PD GENEration: Mapping the Future of Parkinson's Disease pilot study (NCT04057794), approximately 17% of all participants tested positive for genetic mutations linked to Parkinson
- FDA Grants Orphan Drug Designation for Primary Mitochondrial Myopathies Treatmenthttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-for-primary-mitochondrial-myopathies-treatment/2469310/The Food and Drug Administration (FDA) office of orphan products development has granted orphan drug designation to a peroxisome proliferator-activated receptor (PPAR) delta agonist, (REN001; Reneo Pharmaceuticals, San Diego, CA), for the treatment of primary mitochondrial myopathies (PMM).
- New Indication for Pimavanserin—Dementia Related Psychosis—Submitted to the FDAhttps://practicalneurology.com/news/new-indication-for-pimavanserin-dementia-related-psychosis-submitted-to-the-fda/2469301/A supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaseuticals, San Diego, CA) was submitted to the Food and Drug Administration (FDA) for a new indication. Evidence now shows pimavanserin is effective for the treatment of hallucinations and delusions associated wit
- Phase 2 Clinical Trial of LSD for Cluster Headaches Initiatedhttps://practicalneurology.com/news/phase-2-clinical-trial-of-lsd-for-cluster-headaches-initiated/2469288/A phase 2 trial (NCT03781128) for lysergic acid diethylamide (LSD) pulse regimen (Mind Medicine, Basel, Switzerland) for cluster headache treatment started recruiting participants in
- FDA Approves Opicapone as Adjunctive to Levodopa for Parkinson Diseasehttps://practicalneurology.com/news/fda-approves-opicapone-as-adjunctive-to-levodopa-for-parkinson-disease/2469240/The US Food and Drug Administration (FDA) has approved once-daily oral opicapone (Ongentys, Neurocrine Biosciences, San Diego, CA) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in individuals with Parkinson disease (PD) experiencing off episodes. Opicapone also increases o
- Diazepam Nasal Spray is Commercially Available for Seizure Treatmenthttps://practicalneurology.com/news/diazepam-nasal-spray-is-commercially-available-for-seizure-treatment/2469176/Diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) is now commercially available. The Food and Drug Administration (FDA) approved diazepam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in January 2020. "We understa
- FDA Approves Diazepam Nasal Spray For Acute Treatment of Seizure Clustershttps://practicalneurology.com/news/fda-approves-diazepam-nasal-spray-for-acute-treatment-of-seizure-clusters/2469129/The Food and Drug Administration (FDA) has approved a diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) as an acute treatment of intermittent stereotypic episodes of frequent seizure activity. The treatment is indicated for seizure clusters and acute repetit
- More Sites Offer Free Parkinson Disease Genetic Testing and Counselinghttps://practicalneurology.com/news/more-sites-offer-free-parkinson-disease-genetic-testing-and-counseling/2469122/The Parkinson's Foundation has added 5 new sites for PD GENEration: Mapping the Future of Parkinson's Disease, a first-of-its-kind national initiative that offers free genetic testing and counseling for clinically relevant Parkinson disease (PD)-related genes. The new sites include Massac
- Study Shows Obesity May be an Early Sign of Dementia And Not a Causehttps://practicalneurology.com/news/study-shows-obesity-may-be-an-early-sign-of-dementia-and-not-a-cause/2469115/A large study has found that obesity in midlife is linked to a greater risk of dementia later in life; however, poor diet and lack of exercise are not. The study is published in the December 18, 2019, online issue of
- First-In-Human Study Results Show PTI-125, An Investigational Agent, Reduces Biomarkers of Alzheimer’s Disease, Inflammation, and Neurodegenerationhttps://practicalneurology.com/news/first-in-human-study-results-show-pti-125-a-investigational-agent-reduces-biomarkers-of-alzheimers-disease-inflammation-and-neurodegeneration/2469106/At the Clinical Trials in Alzheimer Disease meeting in San Diego, CA December 4-7, 2019, results of an open label first-in-human clinical trial (NCT03748706) of PTI-125 (Cassava Sciences, Austin, TX) were presented. An investigati